… highlights significant potential of ProQR’s Axiomer ® RNA base-editing platform and strengthens financial position … highlight clinical stage pipeline programs and Axiomer ® RNA editing platform LEIDEN, Netherlands & CAMBRIDGE, Mass., … partnership we entered into with Lilly around our Axiomer RNA base-editing platform and the appointment of Theresa …
… into a research collaboration to apply the Axiomer ® RNA editing technology to fibrosis targets selected by … loss associated with Usher syndrome type 2A. ADAR A-to-I RNA editing expert Dr. Peter A. Beal was appointed to ProQR’s … of RNA-based therapeutics, particularly in the area of RNA editing. As an expert in the field of ADAR and A-to-I …
… ProQR is accelerating the development of its Axiomer ® RNA base-editing technology platform across multiple therapeutic areas … ProQR is accelerating the development of its Axiomer RNA editing platform and pipeline activities and plans to …
ProQR and Ginkgo Bioworks to collaborate on autonomous lab high throughput data generation to support ProQR’s AI-enabled drug discovery for Axiomer™ProQR establishes AI Advisory Board with leaders from industry and academiaProQR’s first AI-discovered Development
… and other DEB mutations An introduction to ProQR’s novel RNA editing platform technology called Axiomer LEIDEN, the … the promising pipeline of discovery programs and a novel RNA editing technology.” “Over the last several decades the … scientific efforts have also led to a novel proprietary RNA editing platform, called Axiomer, which in our view is …
… ProQR’s strategic focus on its proprietary Axiomer ® RNA editing technology platform and continued advancement of … “We look forward to continuing to advance our Axiomer RNA editing platform, with an initial focus on targets for …
… of the Company’s novel and proprietary next generation RNA editing technology, Axiomer®, that utilizes endogenous RNA editing processes to target a number of genetic … and our broader RNA technologies, including the Axiomer® RNA editing platform that was recently introduced at the …
… RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the Annual … the Company in the translation of Axiomer, our leading RNA editing platform technology, to the clinic. His expertise … Axiomer platform, the therapeutic potential of our Axiomer RNA editing oligonucleotides, and the potential of our …